






La Marca, A., Niederberger, C., Pellicer, A. and Nelson, S. M. (2020) COVID-19: 
lessons from the Italian reproductive medical experience. Fertility and Sterility, 113(5), 
pp. 920-922. 
 
   
There may be differences between this version and the published version. You are 




http://eprints.gla.ac.uk/212934/   






























Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk  
  
COVID-19: The Reality for Italian Reproductive Medicine  
Antonio La Marca1 
Antonio Pellicer2 
Scott M Nelson3 
 
1Department of Medical and Surgical Sciences for Children and Adults, University 
of Modena and Reggio Emilia, Modena, Italy	
2IVIRMA Valencia, Valencia, Spain 








On 31 December 2019 the Health Commission of Hubei Province, China announced a cluster 
of unexplained cases of pneumonia. Isolation and genome sequencing of the virus identified 
it as the 2019 novel coronavirus (2019-nCoV). On the 11 February 2020, the International 
Committee on Taxonomy of Viruses defined the virus as "Acute severe respiratory syndrome 
coronavirus 2" (SARS-CoV-2), with the associated respiratory disease COVID-19 (CO-rona 
VI-rus D-isease 2019).  The COVID-19 pandemic has brought unique challenges to the 
global healthcare community, with rapid escalation of the number of affected individuals and 
associated mortality over recent weeks. Clinical and public health guidance has primarily 
focused on minimising the potential health impact using the best available scientific advice 
and evidence to inform decision making to help contain the virus, delay its spread and 
mitigate its effect on infected individuals.  Countries have adopted individualised timing of 
risk reduction strategies reflecting their differential risk assessments, with Italy having the 
largest number of affected cases outside of China. The impact and reorganisation of clinical 
services that have been required by Italy may be faced by many of us in the weeks ahead 
given the anticipated trajectory of COVID-19 globally.  
 
The COVID-19 epidemic in Italy started on January 30, when two Chinese tourists tested 
positive. An outbreak was subsequently detected from few patients in Lombardy on 21 
February, which had already become 60 patients the next day. As of March 13, 2020, there 
were 14 955 positive cases of coronavirus, including 1 439people healed and 1266 people 
dead, and 73 154 swabs were made for the virus. Among the measures to contain the 
infection, as early as February, 11 municipalities had been quarantined. Nobody could enter 
and leave those territories. Following the expansion of the areas with confirmed infection, the 
area of limitation of human activities was extended to various northern regions (Lombardy, 
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Emilia, Veneto) and from the 9th of March to the entire country with 60 million citizens being 
placed in lockdown.  
 
The societal and economic impact of these changes cannot be underestimated, all schools are 
closed requiring childcare to be provided at home, social and professional meetings cancelled, 
closure of public spaces, the mobility of people restricted to only attend work or for health 
reasons, and closure of many businesses including all restaurants and entertainment venues. 
These measures are combined with existing recommendations from the World Health 
Organisation to wash your hands frequently, avoid touching your eyes, nose and mouth, 
cover your mouth and nose if you sneeze or cough with a tissue, dispose of it immediately 
and wash your hands, keep the interpersonal distance of at least one meter and avoid 
gatherings and use a surgical mask in the presence of people suspected of being sick. The 
primary aim of these measures is to flatten the growth curve of new cases, thereby reducing 
the number of people who will simultaneously require intensive care and overall mortality.  
As of 11 March 2020, 1028 of the approximately 5200 intensive care beds within Italy were 
already occupied with COVID-19 patients (1).  Parallel to these governmental directives, the 
Ministry of Health has undertaken extensive reorganisation of national healthcare provision 
to facilitate the treatment of the totality of patients who will need intensive support therapy.  
 
Professional bodies including the American College of Obstetrics and Gynecology (ACOG) 
(2) and the British Royal College of Obstetricians and Gynaecologists (RCOG) (3) have 
provided specific guidance for pregnant women as based on very limited data and previous 
coronaviruses (SARS-CoV and MERS-CoV): pregnant women may be at higher risk of 
severe illness, morbidity, or mortality compared with the general population and adverse 
perinatal outcomes including preterm birth (4,5). For women considering pregnancy or 
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embarking on assisted conception there is substantially more limited evidence. Given the 
modelling of the pandemic including the time to peak and subsequent tail, considerable 
delays in conception to substantially mitigate risk would be required, which will inevitably 
impact on the overall success rates.  
 
Reproductive Medicine Units that continue to offer clinical treatments necessitate specific 
changes to the organization. These include strict adherence to the generic health precautions 
with clearly visible signs within the clinics at the entrance and throughout the clinics 
including private spaces to remind patients of these general measures. You may reduce 
exposure to external meetings by cancelling attendance and all staff have considered personal 
risk when commuting. All non-essential visits by external businesses or academic 
collaborators should be avoided and can be replaced by web platforms. Patient information 
events may be taken with webinars.  Out-patient consultations can be moved to a 
telemedicine model where feasible, with strict adherence to timetabled appointments for 
ultrasounds and bloods to reduce waiting room exposure coupled with asking patients to 
attend alone and to wait outside in car until scheduled appointment to reduce overall footfall 
and risk of transmission. Working agendas are to be altered to reduce the sharing of common 
spaces by staff, including the creation of shift teams to reduce the risk that the whole clinic 
staff is affected and may be required to self-isolate. Managerial, administrative and IT staff 
are similarly to be moved to a rotating rota of shared work / remote working to reduce the 
risk of all being infected simultaneously. Access to common areas of the clinic must be 
strictly limited, with deliveries dropped outside at specific entrances. All staff must be trained 
in the processes and protocols for dealing with COVID-19 cases and use of general 
precautions and FFP2 face masks to reduce transmission. Should the team members 
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themselves present with respiratory symptoms, the Italian Authorities have suggested that if 
accompanied by a fever, they are required to abstain from work.  
 
For patients, it is very useful to develop a written multi-lingual summary of the relationship 
and evidence base of coronavirus with pregnancy, including frequently asked questions 
which align with international guidance and are under daily review that is available both 
online and within the clinics.  Patients should be screened for risk by telephone prior to 
attendance and if they are suspected to have an acute respiratory infection (with at least one 
of the following symptoms: fever, cough, dyspnoea); or they were in the previous 14 days in 
a country with community transmission of the virus according to the CDC; or in close contact 
with a confirmed case of Covid-19; or have been in a  hospital where COVID19 patients are 
hospitalized, they can be considered at risk of being positive to the virus and must be asked 
not to present to the clinic and to  postpone the  treatment. The websites must be updated, 
with reminders on the footers of all correspondence regarding COVID-19, including those 
sent by SMS.  Upon entering the clinic, patients are interviewed again regarding the presence 
of respiratory symptoms or at-risk behaviour. 
 
Despite all these screening measures, should medical staff suspect that the patient has 
COVID-19, a strict protocol is invoked. The healthcare staff allocate the patient to a specific 
insulated room and wear the following protective health equipment; waterproof gown, FFP2 
face mask, eye protection and double gloves, the patient is also provided with a face mask. 
During the consultation the decisions will depend on the stage at which the treatment is. If the 
patient is positive during ovarian stimulation the optimal solution is to cancel the cycle with 
the financial implications of this differing between clinics with some choosing to bear the 
cost and others recouping costs to date from the patient.   If the patient already had oocyte 
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retrieval, then cryostorage of oocytes or embryos will be undertaken with avoidance of 
embryo transfer until disease free, due to the risks of further disease deterioration particularly 
during pregnancy.   On completion of the consultation and explanation of deferment of 
treatment the patient is transported outside the clinic, using a predetermined route to 
minimize the possible exposure of health personnel, other patients and visitors. All rooms and 
areas are then carefully sanitized, using an alcohol-based disinfectant containing ≥75% 
alcohol or 5% chlorine based. After use, the disposable protective devices are carefully 
removed, with folding in on themselves, with hand sanitisation at the different stages of 
removal with alcohol gel before being finally disposed of in the appropriate containers for 
infected waste. The patient is then notified to the appropriate regional or national centre.  
 
For patients receiving ovarian stimulation mitigation of the risk of (ovarian hyperstimulation 
syndrome (OHSS) is paramount, as COVID-19 infection in a woman experiencing the 
hypovolemic and electrolyte imbalance typically associated to the syndrome, may lead to an 
exponential risk of lung and kidney complications. Hence the use of mild stimulation, GnRH 
antagonist control of the LH surge, GnRH agonist triggering and single embryo transfer or 
freeze all, are the first choice in this period for women entering the IVF programme 
 
The Italian authorities have established that even in the absence of evidence of transmission 
of the virus within reproductive cells, all donors should be interviewed regarding the presence 
of respiratory symptoms and for recent travel to high-risk areas. For   donors who have 
returned from at risk area, a two-week suspension is required, and in case they have 
respiratory symptoms a two-week suspension from the end of symptoms is required, as 
compared to the 28-day period recommended by the Joint UK Blood Transfusion and Tissue 
Transplantation Services Professional Advisory Committee (JPAC).  For homologous fertility 
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treatments there are no specific restrictions at regulatory level except for patients with 
symptoms in progress suggestive for COVID-19, as noted above with separate closed 
cryostorage systems in place. In the case of importation of gametes from abroad there is a 
need to have an additional declaration from the sending centre where the risks of SARS-CoV-
2 infection for the specific donor have been assessed. The declaration is necessary only for 
new donations and not for cryopreserved material prior to the SARS-CoV-2 outbreak. 
Patients have been advised not to pursue fertility tourism due to the strict travel bans in place.  
 
As the Italian experience is highly likely to replicate in other countries, the epidemy will 
proceed at a pace that may lead governments to severely limit human activities including all 
travel outside the home and non-essential healthcare. For this scenario we anticipate further 
reduction in clinical activity, with continuation of only non-deferrable healthcare activities. 
Although stimulation cycles could be cancelled, we anticipate that completion of ongoing 
ovarian stimulation with segmentation of the cycle will be feasible.  
 
COVID-19 is an unprecedented challenge to our healthcare systems.  The impact that we 
have observed in Italy and the strategies that we have developed will continue to be refined as 
multidisciplinary teams across the world continue to examine all aspects of this disease 
including pregnancy and neonatal outcomes, enabling accurate guidance for the professional 
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